New Zealand - English - Medsafe (Medicines Safety Authority)
Page 1 of 3
NEW ZEALAND CONSUMER MEDICINE INFORMATION
CEFUROXIME FOR INJECTION
Cefuroxime Sodium Injection Powder
250 mg, 750 mg, 1.5 g
What is in this leaflet
This leaflet answers some common
questions about CEFUROXIME
It does not contain all the available
information. It does not take the
place of talking to your doctor or
All medicines have risks and
benefits. Your doctor has weighed
the risks of you using
CEFUROXIME INJECTION against
the benefits they expect it will have
If you have any concerns about
using this medicine, ask your
doctor or pharmacist.
Keep this leaflet with the
medicine. You may need to read it
INJECTION is used
CEFUROXIME INJECTION is an
antibiotic used to treat a wide range
of infections caused by bacteria and
also to prevent infections during
surgery. It can be given to adults
contains the active ingredient
cefuroxime sodium. It belongs to a
group of medicines called
cephalosporin antibiotics which
targets a wide range of common
bacteria. It works by killing the
bacteria causing the infection or
preventing cell growth.
CEFUROXIME INJECTION is used
in adults and children to treat
bacterial infections of the:
lungs or chest (bronchitis,
ears, nose and throat
bones and joints
female reproductive organs
CEFUROXIME INJECTION can
also be used to:
treat gonorrhoea, a sexually
prevent infections during
Ask your doctor if you have any
questions about why this
medicine has been prescribed for
Your doctor may have prescribed it
for another reason.
This medicine is not addictive.
This medicine is available only with
a doctor’s prescription.
Before you are given
When you must not be
Do not use CEFUROXIME
INJECTION if you have an allergy
any medicine containing
any penicillins or any other
any other cephalosporin
Some of the symptoms of an
allergic reaction may include:
shortness of breath; wheezing or
difficulty breathing; swelling of the
face, lips, tongue or other parts of
the body; rash, itching or hives on
Before you start to use it
Tell your doctor if you have
allergies to any other medicines,
foods, preservatives or dyes.
Tell your doctor if you have or
have had any of the following
kidney problems, with extra
caution in the elderly.
Tell your doctor if you are
pregnant or plan to become
pregnant or are breast-feeding.
Your doctor can discuss with you
the risks and benefits involved.
There is no experimental evidence
of birth defects attributable to
however; all medicines should be
administered with caution.
CEFUROXIME INJECTION is
passed though breast milk.
If you have not told your doctor
about any of the above, tell
him/her before you start using
Taking other medicines
Tell your doctor or pharmacist if
you are taking any other
medicines, including any that you
get without a prescription from
your pharmacy, supermarket or
health food shop.
Some medicines and
CEFUROXIME INJECTION may
interfere with each other. These
Page 2 of 3
water tablets (diuretics),
such as furosemide
These medicines may be affected
by CEFUROXIME INJECTION or
may affect how well it works. You
may need different amounts of your
medicines, or you may need to take
Your doctor and pharmacist have
more information on medicines to
be careful with or avoid while using
INJECTION is given
CEFUROXIME INJECTION can be
given in three ways:
as an injection into the
as an injection into a vein
as a drip (intravenous
CEFUROXIME INJECTION must
only be given by a doctor or a
Your doctor will decide on the dose
and length of time that you will
receive CEFUROXIME INJECTION.
Use the medicine for as long as the
Follow all directions given to you
by your doctor or pharmacist
They may differ from the information
contained in this leaflet.
CEFUROXIME INJECTION is
generally given alone although
sometimes your doctor may
prescribe it in combination with
another type of antibiotic called an
aminoglycoside or together with an
antibacterial agent called
If too much
INJECTION is given
Immediately telephone your
doctor or the National Poisons
Information Centre (0800 POISON
or 0800 764 766) for advice, or go
to Accident and Emergency at
the nearest hospital, if you think
that you or anyone else may have
used too much CEFUROXIME
INJECTION. Do this even if there
are no signs of discomfort or
poisoning. You may need urgent
Symptoms of an overdose may
While you are using
Things you must do
If you are about to be started on
any new medicine, remind your
doctor and pharmacist that you
are using CEFUROXIME
Tell any other doctors, dentists,
and pharmacists who treat you
that you are using this medicine.
If you are going to have surgery,
tell the surgeon or anaesthetist
that you are using this medicine.
It may affect other medicines used
If you become pregnant while
using this medicine, tell your
If you are about to have any
blood tests, tell your doctor that
you are using this medicine.
It may interfere with the results of
Things you must not do
Do not use CEFUROXIME
INJECTION to treat any other
complaints unless your doctor
tells you to.
Do not stop using your medicine
or lower the dosage without
checking with your doctor.
Things to be careful of
Be careful driving or operating
machinery until you know how
CEFUROXIME INJECTION affects
This medicine may cause dizziness
in some people. If you feel dizzy, do
not drive, operate machinery or do
anything else that could be
Tell your doctor or pharmacist as
soon as possible if you do not
feel well while you are using
This medicine helps most people
with bacterial infections, but it may
have unwanted side effects in a few
people. All medicines can have side
effects. Sometimes they are
serious, most of the time they are
not. You may need medical
attention if you get some of the side
Do not be alarmed by the
following lists of side effects.
You may not experience any of
Ask your doctor or pharmacist to
answer any questions you may
Tell your doctor or pharmacist if
you notice any of the following
and they worry you:
white furry, sore tongue and
mouth (oral thrush)
sore, itchy vagina and/or
discharge (vaginal thrush)
swelling and redness along
swelling, pain or tenderness
at the injection site
diarrhoea, abdominal pain
tendency to bruise or bleed
The above list includes the more
common side effects that are
usually mild and short-lived.
Page 3 of 3
Tell your doctor as soon as
possible if you notice any of the
signs of an allergic reaction,
such as shortness of
breath, wheezing or
difficulty breathing, swelling
of the face, lips, tongue or
other parts of the body;
rash, itching or hives on the
chills or fever, which may
be accompanied by
ringing in the ears or
low blood pressure
prolonged or severe
diarrhoea or stomach
The above list includes serious side
effects that may require medical
attention. Serious side effects are
The medicine should be kept in
the packaging until it is time to
CEFUROXIME INJECTION should
be kept in a cool, dry place where
the temperature stays below 25°C.
CEFUROXIME INJECTION or any
other medicine should not be stored
in the bathroom or near a sink.
Heat and dampness can destroy
CEFUROXIME INJECTION should
be stored where children cannot
A locked cupboard at least one-and-
a half metres above the ground is a
good place to store medicines.
What it looks like
CEFUROXIME INJECTION is a
white to faintly yellow powder to
which water is added to prepare an
off-white suspension for
intramuscular use or a yellow
solution for intravenous
administration. Colour of the
suspension may vary.
CEFUROXIME INJECTION is
supplied in vials which contain 250
mg, 750 mg, or 1.5g of cefuroxime
sodium powder for injection or
Not all strengths may be marketed.
CEFUROXIME contains 250 mg,
750 mg, or 1.5 g of cefuroxime
sodium as the active ingredient.
This medicine does not contain
lactose, sucrose, gluten, tartrazine
or any other azo dyes.
If you want to know
Should you have any questions
regarding this product, please
contact your pharmacist or doctor.
Who supplies this
Distributed in New Zealand by:
Mylan New Zealand Ltd,
PO Box 11183,
Telephone: (09) 579 2792.
Date of Information
24 February 2017
(Based on datasheet dated
24 February 2017).
Page 1 of 11
NEW ZEALAND DATA SHEET
CEFUROXIME FOR INJECTION
1. Product Name
Cefuroxime for injection, 250mg, 750 mg, 1.5 g, powder for injection.
2. Qualitative and Quantitative Composition
Each vial contains 263 mg, 789 mg or 1.578 g of cefuroxime sodium, equivalent to 250 mg, 750
mg or 1.5 g of cefuroxime.
3. Pharmaceutical Form
Cefuroxime is a white to faintly yellow powder to which appropriate amounts of water are added to
prepare an off-white suspension for intramuscular use or a yellow solution for intravenous
Variations in the intensity of this colour do not indicate any change in either the efficacy or safety of
4. Clinical Particulars
Cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most β-lactamases and is
active against a wide range of Gram-positive and Gram-negative organisms.
It is indicated for the treatment of infections before the infecting organism has been identified or
when caused by sensitive bacteria.
Susceptibility to cefuroxime sodium will vary with geography
and time and local susceptibility data should be consulted where available (see section 5.1).
Respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial
pneumonia, lung abscess and post-operative chest infections.
Ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media.
Soft-tissue infections for example, cellulitis, erysipelas and wound infections.
Bone and joint infections for example, osteomyelitis and septic arthritis.
Obstetric and gynaecological infections, pelvic inflammatory diseases.
Gonorrhoea particularly when penicillin is unsuitable.
Other infections including septicaemia, meningitis and peritonitis.
Prophylaxis against infection in abdominal, pelvic, orthopaedic, cardiac, pulmonary, oesophageal and
vascular surgery where there is increased risk from infection.
Usually cefuroxime will be effective alone, but when appropriate it may be used in combination with
an aminoglycoside antibiotic, or in conjunction with metronidazole (orally or by suppository or
injection), especially for prophylaxis in colonic or gynaecological surgery (see section 6.6).
Page 2 of 11
Where appropriate cefuroxime sodium is effective when used prior to oral therapy with cefuroxime
axetil in the treatment of pneumonia and acute exacerbations of chronic bronchitis.
Dose and method of administration
Many infections respond to 750 mg three times daily by intramuscular or intravenous injection. For
more severe infections the dose should be increased to 1.5 g three times daily given intravenously.
The frequency of administration may be increased to 6-hourly if necessary, giving total daily doses
of 3 to 6 g. Where clinically indicated, some infections respond to 750 mg or 1.5 g twice daily
(intravenously or intramuscularly) followed by oral therapy with cefuroxime axetil.
Infants and children
30 to 100 mg/kg/day given as 3 or 4 divided doses. A dose of 60 mg/kg/day is appropriate for most
30 to 100 mg/kg/day given as 2 or 3 divided doses (see section 5.2).
Cefuroxime is excreted by the kidneys. Therefore, as with all such antibiotics, in patients with
markedly impaired renal function it is recommended that the dosage of cefuroxime should be
reduced to compensate for its slower excretion.
It is not necessary to reduce the standard dose (750 mg to 1.5 g three times daily) until the
creatinine clearance falls to 20 mL/min or below.
In adults with marked impairment (creatinine clearance 10 to 20 mL/min) 750 mg twice daily is
recommended and with severe impairment (creatinine clearance <10 mL/min) 750 mg once daily is
intramuscularly at the end of each dialysis. In addition to parenteral use, cefuroxime can be
incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 litres of dialysis fluid).
For patients in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration
in intensive therapy units a suitable dosage is 750 mg twice daily. For low-flux haemofiltration
follow the dosage recommended under Impaired Renal Function.
1.5 g as a single dose (as 2 x 750 mg injections given intramuscularly with different sites, e.g. each
Cefuroxime is suitable for sole therapy of bacterial meningitis due to sensitive strains.
3 g given
intravenously every eight hours.
Infants and children
150 to 250 mg/kg/day given intravenously in 3 or 4 divided doses.
Page 3 of 11
The dosage should be 100 mg/kg/day given intravenously.
The usual dose is 1.5 g given intravenously with induction of anaesthesia for abdominal, pelvic and
orthopaedic operations. This may be supplemented with two 750 mg intramuscular doses 8 and 16
In cardiac, pulmonary, oesophageal and vascular operations, the usual dose is 1.5 g given
intravenously with induction of anaesthesia, continuing with 750 mg given intramuscularly three
times daily for a further 24 to 48 hours.
In total joint replacement, 1.5 g cefuroxime powder may be mixed dry with each pack of methyl
methacrylate cement polymer before adding the liquid monomer.
Cefuroxime is also available as the axetil ester for oral administration. This permits parenteral
therapy with cefuroxime to be followed by oral therapy in situations where a change from
parenteral to oral is clinically indicated.
Duration of both parenteral and oral therapy is determined by the severity of the infection and the
clinical status of the patient.
intramuscularly) for 48 to 72 hours, followed by 500 mg twice daily cefuroxime axetil oral therapy
for 7 to 10 days.
Acute Exacerbations of Chronic Bronchitis: 750 mg cefuroxime three times daily or twice daily
(given intravenously or intramuscularly) for 48 to 72 hours, followed by 500 mg twice daily
cefuroxime axetil oral therapy for 5 to 10 days.
Method of administration
Cefuroxime for Injection – for intravenous (IV) and/or intramuscular (IM) administration.
No more than 750 mg should be injected at one intramuscular site.
For intravenous infusion the solution may be administered directly into the vein or introduced into
the tubing of the giving set if patient is receiving parenteral fluid.
For instructions on preparation of the medicinal product before administration, see section 6.6.
Cefuroxime is contraindicated in patients who have had previous experience of a major allergy or
anaphylaxis to a cephalosporin or penicillin.
Special warnings and precautions for use
Cefuroxime should be given with caution to patients who have experienced symptoms of allergy
associated with a cephalosporin or penicillin.
Special care is indicated in patients who have experienced an allergic reaction to penicillins or
Cephalosporin antibiotics at high dosage should be given with caution to patients receiving
concurrent treatment with potent diuretics such as furosemide or aminoglycosides, as renal
impairment has been reported with these combinations. Renal function should be monitored in
these patients, the elderly, and those with pre-existing renal impairment (see section 4.2).
Page 4 of 11
As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing
loss has been reported in a few paediatric patients treated with cefuroxime sodium. Persistence of
positive cerebral spinal fluid (CSF) cultures of Haemophilus influenzae at 18 to 36 hours has also
been noted with cefuroxime sodium injection, as well as with other antibiotic therapies; however,
the clinical relevance of this is unknown.
As with other antibiotics, use of cefuroxime may result in the overgrowth of Candida. Prolonged
use may also result in the overgrowth of other non-susceptible organisms (e.g. enterococci and
Clostridium difficile), which may require interruption of treatment.
reported with virtually all broad spectrum antibiotics and may range in severity from mild to life-
threatening. It is important to consider this diagnosis in patients who develop diarrhoea in
association with the use of cefuroxime.
Drugs which delay peristalsis may prolong and/or worsen
the condition and should not be used.
If prolonged or significant diarrhoea occurs or the patient
experiences abdominal cramps, treatment should be discontinued immediately and the patient
Prothrombin time – Prolonged prothrombin time may occur in patients receiving protracted
With a sequential therapy regime the timing of change to oral therapy is determined by severity of
the infection, clinical status of the patient and susceptibility of the pathogens involved. If there is no
clinical improvement within 72 hours, then the parenteral course of treatment must be continued.
Refer to the relevant prescribing information for cefuroxime axetil before initiating sequential
Interaction with other medicines and other forms of interaction
In common with other antibiotics cefuroxime may affect the gut flora, leading to lower oestrogen
reabsorption and reduced efficacy of combined oral contraceptives.
Cefuroxime does not interfere in enzyme-based tests for glycosuria.
observed. However, this should not lead to false-positive results, as may be experienced with
some other cephalosporins.
It is recommended that either the glucose oxidase or hexokinase methods are used to determine
blood/plasma glucose levels in patients receiving cefuroxime.
This antibiotic does not interfere in the alkaline picrate assay for creatinine.
See also section 6.2 and 6.6.
Fertility, pregnancy and lactation
cefuroxime, but, as with all medicines, it should be administered with caution during the early
months of pregnancy.
Cefuroxime is excreted in human milk, and consequently caution should be exercised when
cefuroxime is administered to a nursing mother.
Page 5 of 11
No data available. For pre-clinical fertility data refer to section 5.3.
Effects on ability to drive and use machines
During treatment with cefuroxime, undesirable effects may occur (e.g. dizziness), which may
influence the ability to drive and use machines. Patients should be cautious when driving or
authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance
of the medicine. Healthcare professionals are asked to report any suspected adverse reactions
Adverse drug reactions are very rare (<1/10,000) and are generally mild and transient in nature.
The frequency categories assigned to the adverse reactions below are estimates, as for most
reactions suitable data for calculating incidence are not available. In addition the incidence of
adverse reactions associated with cefuroxime sodium may vary according to the indication.
Data from clinical trials were used to determine the frequency of very common to rare undesirable
<1/10,000) were mainly determined using post-marketing data, and refer to a reporting rate rather
than a true frequency.
The following convention has been used for the classification of frequency:
Very common ≥ 1/10,
≥ 1/100 and < 1/10,
≥ 1/1000 and < 1/100,
≥ 1/10,000 and < 1/1000,
Infections and infestations
Rare: Candida overgrowth.
Blood and lymphatic system disorders
Common: Neutropenia, eosinophilia.
Uncommon: Leukopenia, decreased haemoglobin concentration, positive Coomb’s test.
Very rare: Haemolytic anaemia.
Cephalosporins as a class tend to be absorbed onto the surface of red cell membranes and react
with antibodies directed against the drug to produce a positive Coomb’s Test (which can interfere
with cross matching of blood) and very rarely haemolytic anaemia.
Immune system disorders
Hypersensitivity reactions including:
Uncommon: Skin rash, urticaria and pruritus.
Rare: Drug fever.
Very rare: Interstitial nephritis, anaphylaxis, cutaneous vasculitis.
Common: Thrombophlebitis may follow intravenous injection.
Page 6 of 11
Uncommon: Gastrointestinal disturbance.
Very rare: Pseudomembranous colitis (see section 4.4).
Common: Transient rise in liver enzymes.
Uncommon: Transient rise in bilirubin.
Transient rises in serum liver enzymes or bilirubin occur, particularly in patients with pre-existing
liver disease, but there is no evidence of harm to the liver.
Skin and subcutaneous tissue disorders
Very rare: Erythema multiforme, toxic epidermal necrolysis and Stevens Johnson Syndrome.
Renal and urinary disorders
Very rare: Elevations in serum creatinine, elevations in blood urea nitrogen and decreased
creatinine clearance (see section 4.4).
General disorders and administration site conditions
Common: Injection site reactions which may include pain and thrombophlebitis
Pain at the intramuscular injection site is more likely at higher doses. However it is unlikely to be a
cause for discontinuation of treatment.
Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. Serum levels of
cefuroxime can be reduced by haemodialysis or peritoneal dialysis.
For further advice on management of overdose please contact the National Poisons Information
Centre (0800 POISON or 0800 764 766).
5. Pharmacological Properties
Pharmacotherapeutic group: antibacterials for systemic use, second generation cephalosporins,
ATC code: J01DC02
Mechanism of action
Cefuroxime is a well characterised and effective antibacterial agent which has bactericidal activity
against a wide range of common pathogens, including β-lactamase producing strains.
Cefuroxime has good stability to bacterial β-lactamase, and consequently is active against many
ampicillin-resistant or amoxicillin-resistant strains.
The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to
essential target proteins.
Page 7 of 11
The prevalence of acquired resistance is geographically and time dependent and for select species
may be very high. Local information on resistance is desirable, particularly when treating severe
In vitro susceptibility of micro-organisms to Cefuroxime
Where clinical efficacy of cefuroxime has been demonstrated in clinical trials this is indicated with
an asterisk (*).
Commonly susceptible species
Staphylococcus auereus (methicillin susceptible)*
Coagulase negative staphylococcus (methicillin susceptible)
Haemophilus influenzae, including ampicillin-resistant strains*
Neisseria gonorrhoeae* including penicillinase and non-penicillinase producing strains
Organisms for which acquired resistance may be a problem
Viridans group streptococcus
Citrobacter spp. not including C. freundii
Enterobacter spp. not including E. aerogenes and E. cloacae
Klebsiella spp. including K. pneumoniae*
Proteus spp. not including P. penneri and P. vulgaris
Clostridium spp. not including C. difficile
Bacteroides spp. not including B. fragilis
Inherently resistant organisms
Page 8 of 11
Enterococcus spp. including E. faecalis and E. faecium
Pseudomonas spp. including P. aeruginosa
Peak levels of cefuroxime are achieved within 30 to 45 minutes after intramuscular administration.
Protein binding has been variously stated as 33 to 50% depending on the methodology used.
Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens
can be achieved in bone, synovial fluid and aqueous humour. Cefuroxime passes the blood-brain
barrier when the meninges are inflamed.
Cefuroxime is not metabolised and is excreted by glomerular filtration and tubular secretion
The serum half-life after either intramuscular or intravenous injection is approximately 70 minutes.
In the first weeks of life the serum half-life of cefuroxime can be 3 to 5 times that in the adult.
Concurrent administration of probenecid prolongs the excretion of the antibiotic and produces an
elevated peak serum level. There is an almost complete recovery (85-90%) of unchanged
cefuroxime in urine within 24 hours of administration. The major part is excreted in the first six
hours. Serum levels of cefuroxime are reduced by dialysis.
Preclinical safety data
Page 9 of 11
Non-clinical data reveal no special hazard for humans based on conventional studies of safety
reproduction and development.
6. Pharmaceutical Particulars
List of excipients
Cefuroxime should not be mixed in the syringe with aminoglycoside antibiotics.
The pH of 2.74% w/v Sodium Bicarbonate Injection BP considerably affects the colour of the
solution and therefore this solution is not recommended for the dilution of cefuroxime. However, if
required, for patients receiving Sodium Bicarbonate Injection by infusion the cefuroxime may be
introduced into the tube of the giving set.
After reconstitution, Cefuroxime Mylan should be stored at 2 - 8°C for no longer than 24 hours.
Suspensions of cefuroxime for intramuscular injection and aqueous solutions for direct intravenous
injection retain their potency for five hours if kept below 25
C and for 24 hours if refrigerated.
Some increase in the colour of prepared solutions and suspensions of cefuroxime may occur on
Special precautions for storage
Store at or below 25°C and protect from light.
For storage conditions after reconstitution of the medicine, see section 6.3.
Nature and contents of container
250 mg: Clear 10 ml glass vial with a halobutyl rubber stopper and flip-off aluminium cap.
size of 1 vial.
750 mg: Clear 10 ml or 15 ml glass vial with a halobutyl rubber stopper and flip-off aluminium cap.
Pack size of 1 or 10 vials.
1.5 g: Clear 10 ml or 15 ml glass vial with a halobutyl
rubber stopper and flip-off aluminium cap.
Pack size of 1 vial.
Not all pack types and sizes may be marketed.
Special precautions for disposal and other handling
Preparation of a Suspension for Intramuscular Injection
Add 1 mL Water for Injections to 250 mg Cefuroxime for Injection or 3 mL Water for Injections to
750 mg Cefuroxime for Injection. Shake gently to produce an opaque suspension.
Preparation of a Solution for Intravenous Injection
Page 10 of 11
250 mg & 750 mg Vials
For reconstitution of the powder dissolve Cefuroxime for Injection in Water for Injections using at
least 2 mL for 250 mg and at least 6 mL for 750 mg.
1.5 g Vial
For reconstitution of the powder
Draw up at least 15 mL of water for injections into a suitable syringe (20 mL).
Transfer 10 mL into the 1.5 g vial and reconstitute the contents of the vial.
Then draw up the dissolved contents of the vial into the same syringe.
Preparation of a Solution for Intravenous Infusion
1.5 g Vial
For intravenous infusions of less than 30 minutes, the contents of the 1.5 g vial may be dissolved
in a 50 mL vial or bag of Water for Injection as follows:
For reconstitution of the powder
Draw up at least 10 mL of water for injections from the 50 mL vial or bag using a suitable
Transfer the 10 mL into the 1.5 g vial and reconstitute the content of the vial.
Then transfer the dissolved contents of the vial into the 50 mL vial or bag.
1.5 g cefuroxime constituted with 15 mL Water for Injections may be added to metronidazole
injection (500 mg/100 mL) and both retain their activity for up to 24 hours below 25
1.5 g cefuroxime is compatible with azlocillin 1 g (in 15 mL) or 5 g (in 50 mL) for up to 24 hours at
C, or 6 hours below 25
Cefuroxime (5 mg/mL) in 5%w/v or 10%w/v Xylitol Injection may be stored for up to 24 hours at
Cefuroxime is compatible with aqueous solutions containing up to 1% lignocaine hydrochloride.
Cefuroxime is compatible with the following more commonly used intravenous infusion fluids. It will
retain potency for up to 24 hours at room temperature in:
Sodium Chloride Injection BP 0.9% w/v.
5% Dextrose Injection BP.
0.18% w/v Sodium Chloride plus 4% Dextrose Injection BP.
5% Dextrose and 0.9% Sodium Chloride Injection.
5% Dextrose and 0.45% Sodium Chloride Injection.
5% Dextrose and 0.225% Sodium Chloride Injection.
10% Dextrose Injection.
10% Invert Sugar in Water for Injection.
Ringer’s Injection USP.
Lactated Ringer’s Injection USP.
M/6 Sodium Lactate Injection.
Compound Sodium Lactate Injection BP (Hartmann’s Solution).
The stability of cefuroxime in Sodium Chloride Injection BP 0.9% w/v and in 5% Dextrose Injection
is not affected by the presence of hydrocortisone sodium phosphate.
Page 11 of 11
Cefuroxime has also been found compatible for 24 hours at room temperature when admixed in
intravenous infusion with:
Heparin (10 and 50 units/mL) in 0.9% Sodium Chloride Injection;
Potassium Chloride (10 and 40 mEqL) in 0.9% Sodium Chloride Injection.
7. Medicines Schedule
8. Sponsor Details
Mylan New Zealand Ltd
PO Box 11183
9. Date of First Approval
11 November 1999
10. Date of Revision of the Text
24 February 2017 Revise to SmPC format, pack size addition.